Director/PDMR Shareholding

BioVentix PLC
30 April 2024
 

Bioventix plc 

 

("Bioventix" or "the Company") 

 

Director Dealing 

 

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that on 29 April 2024 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 11 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at an average price of 4,452 pence per Ordinary Share (the "Purchase"). The Ordinary Shares were purchased under a dividend reinvestment plan ("DRIP"). 

 

Following the Purchase, Bruce Hiscock has a beneficial interest in 789 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company. 

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details. 

 

 

For further information please contact: 

 

Bioventix plc 

Peter Harrison 

 

Chief Executive Officer 

Tel: 01252 728 001 




Cavendish 

Geoff Nash / Simon Hicks 

Nigel Birks / Harriet Ward 

 

Corporate Finance 

ECM 

Tel: 020 7220 0500 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 

 

 

1 

Details of the person discharging managerial responsibilities / person closely associated 

a) 

Name 

Bruce Hiscock 

2. 

Reason for the Notification 

a) 

Position/status 

Chief Financial Officer 

b) 

Initial notification/Amendment 

Initial notification 

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

a) 

Name 

Bioventix Plc 

b) 

LEI 

213800225MHX7LZQY108 

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

a) 

Description of the Financial instrument, type of instrument 

Ordinary Shares of 5 pence each 

Identification code 

GB00B4QVDF07 

b) 

Nature of the transaction 

Purchase of Ordinary Shares 

c) 

Price(s) and volume(s) 

11 Ordinary Shares 

4,552 pence 

d) 

Aggregated information: 

 

·     Aggregated volume 

 

·     Price 

Purchase of 11 Ordinary Shares at 4,452 pence each 

e) 

Date of the transaction 

29 April 2024 

f) 

Place of the transaction 

London Stock Exchange, AIM Market (XLON) 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Bioventix (BVXP)
UK 100

Latest directors dealings